Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Aescap Venture

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 29
Average round size
info
The average size of a deal this fund participated in
$21M
Portfolio companies 12
Rounds per year 1.53
Lead investments 7
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.59
Exits 6
Key employees 2
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Pharmaceutical
  • Biopharma
  • Health Diagnostics
  • Therapeutics
Summary

Aescap Venture appeared to be the VC, which was created in 2005. The venture was found in Europe in The Netherlands. The leading representative office of defined VC is situated in the Amsterdam.

The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the Aescap Venture, startups are often financed by Sunstone Life Science Ventures, Novo Holdings, Atlas Venture. The meaningful sponsors for the fund in investment in the same round are TVM Capital, Sunstone Life Science Ventures, De Hoge Dennen Capital. In the next rounds fund is usually obtained by Johnson & Johnson Development Corporation, Wellcome Trust, TVM Capital.

The overall number of key employees were 2.

The fund has no specific favorite in a number of founders of portfolio startups. If startup sums 3 or 4 of the founder, the chance for it to be financed is low. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United Kingdom. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the most popular fund investment industries, there are Chemical, Health Care. Among the most popular portfolio startups of the fund, we may highlight ProtAffin Biotechnologie, Aquapharm Biodiscovery, EOS (Ethical Oncology Science).

The common things for fund are deals in the range of 10 - 50 millions dollars. The high activity for fund was in 2010. Opposing the other organizations, this Aescap Venture works on 6 percentage points less the average amount of lead investments. Speaking about the real fund results, this VC is 15 percentage points more often commits exit comparing to other organizations. The fund is constantly included in less than 2 deals per year. The increased amount of exits for fund were in 2015.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Aescap Venture:
Typical Co-investors
Aescap Venture is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Aescap Venture:

Funds with similar focus

Funds from The Netherlands
Funds with similar focus located in The Netherlands:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Orphazyme

Biotechnology
Genetics
Health Diagnostics
Therapeutics
$24M09 Jan 2015 Capital Region of Denmark

F-star Therapeutics

Biopharma
Biotechnology
Pharmaceutical
$9M23 Oct 2013 Cambridge, England, United Kingdom

Orphazyme

Biotechnology
Genetics
Health Diagnostics
Therapeutics
$20M07 Sep 2011 Capital Region of Denmark

to-BBB

Biopharma
Biotechnology
Pharmaceutical
$4M03 Feb 2011 Leiden, Zuid-Holland, The Netherlands

i-Optics

Biotechnology
Health Diagnostics
Product Design
$4M01 Nov 2010 The Hague, South Holland, Netherlands

Biocartis

Biotechnology
Health Diagnostics
Medical Device
$35M08 Apr 2010 Lausanne, Vaud, Switzerland

Aquapharm Biodiscovery

Biotechnology
Chemical
Pharmaceutical
$6M05 Apr 2010 United Kingdom, England, United Kingdom

F-star Therapeutics

Biopharma
Biotechnology
Pharmaceutical
$9M06 Jan 2010 Cambridge, England, United Kingdom

Biocartis

Biotechnology
Health Diagnostics
Medical Device
$11M15 Oct 2009 Lausanne, Vaud, Switzerland

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Aescap Venture?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 29
Average round size 21M
Rounds per year 1.53
Peak activity year 2010
Lead investments 7
Follow on index 0.59
Exits 6
Group Appearance index 0.90

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Orphazyme

Biotechnology
Genetics
Health Diagnostics
Therapeutics
$24M09 Jan 2015 Capital Region of Denmark

F-star Therapeutics

Biopharma
Biotechnology
Pharmaceutical
$9M23 Oct 2013 Cambridge, England, United Kingdom

Orphazyme

Biotechnology
Genetics
Health Diagnostics
Therapeutics
$20M07 Sep 2011 Capital Region of Denmark

to-BBB

Biopharma
Biotechnology
Pharmaceutical
$4M03 Feb 2011 Leiden, Zuid-Holland, The Netherlands

i-Optics

Biotechnology
Health Diagnostics
Product Design
$4M01 Nov 2010 The Hague, South Holland, Netherlands

Biocartis

Biotechnology
Health Diagnostics
Medical Device
$35M08 Apr 2010 Lausanne, Vaud, Switzerland

Aquapharm Biodiscovery

Biotechnology
Chemical
Pharmaceutical
$6M05 Apr 2010 United Kingdom, England, United Kingdom

F-star Therapeutics

Biopharma
Biotechnology
Pharmaceutical
$9M06 Jan 2010 Cambridge, England, United Kingdom

Biocartis

Biotechnology
Health Diagnostics
Medical Device
$11M15 Oct 2009 Lausanne, Vaud, Switzerland
Crunchbase icon

Content report

The following text will be sent to our editors: